Gerrit Luit ten Kate

Gerrit Luit ten Kate

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in Atherosclerosis
Verified
Journal Article
Closed access
SOStijn C.H. van Den Oord
Stijn C.H. van Den Oord
ESEric Sijbrands
Eric Sijbrands
GKGerrit Luit ten Kate
Gerrit Luit ten Kate
DKDavid van Klaveren
David van Klaveren
RDRon T. van Domburg
Ron T. van Domburg
ASArend F.L. Schinkel
Arend F.L. Schinkel

1 February 2013 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
GKGerrit Luit ten Kate
Gerrit Luit ten Kate
SOStijn C.H. van Den Oord
Stijn C.H. van Den Oord
ESEric Sijbrands
Eric Sijbrands
ALAad van der Lugt
Aad van der Lugt
NJNico de Jong
Nico de Jong
ASArend F.L. Schinkel
Arend F.L. Schinkel

1 July 2013 in The American Journal of Cardiology
Verified
Journal Article
Closed access
GKGerrit Luit ten Kate
Gerrit Luit ten Kate
ADAnouk C. van Dijk
Anouk C. van Dijk
SOStijn C.H. van Den Oord
Stijn C.H. van Den Oord
BHBurhan Hussain
Burhan Hussain
HVHence J.M. Verhagen
Hence J.M. Verhagen
ASArend F.L. Schinkel
Arend F.L. Schinkel

4 April 2007 in Gut
Verified
Journal Article
Closed access
PDF file
GKGerrit Luit ten Kate
Gerrit Luit ten Kate
JKJ H Kleibeuker
J H Kleibeuker
FNF M Nagengast
F M Nagengast
MCM Craanen
M Craanen
ACA Cats
A Cats
THThomas Hansen
Thomas Hansen
Background: Small bowel cancer (SBC) is one of the tumours associated with Lynch syndrome (LS). To advise on screening for this tumour it is paramount to be informed about the lifetime risk. The aim of this study was to calculate the lifetime risk of SBC in LS and to identify possible risk factors. Methods: Clinical and pathological data were collected on 1496 proven or putative carriers of a mismatch repair gene mutation from 189 families. Kaplan-Meier survival analysis was used to calculate the lifetime risk and to assess potential risk factors. Results: 28 (1.9%) of the 1496 (putative) mutation carriers were identified with SBC. The median age at diagnosis was 52 years (range 23–69 years). The lifetime risk of developing SBC was 4.2%. There was no difference in risk between males and females (log rank: p = 0.2470), or between MLH1 and MSH2 mutation carriers (log rank: p = 0.2754). SBC was not observed in MSH6 mutation carriers (n = 203). The previous occurrence of colorectal cancer and a family history of SBC did not increase the risk significantly. Conclusions: Approximately, one out of 25 mutation carriers will develop SBC during life. No specific risk factors were identified. The risk appeared to be too low to advise screening by means of an invasive burdensome procedure like double balloon enteroscopy. However, screening by a non-invasive procedure (videocapsule endoscopy) might be considered if future studies will show its cost effectiveness. In patients with unexplained abdominal complaints and/or unexplained iron deficiency anaemia SBC should be considered.

1 November 2010 in Current Problems in Cardiology
Verified
Journal Article
Closed access
GKGerrit Luit ten Kate
Gerrit Luit ten Kate
ESEric Sijbrands
Eric Sijbrands
DSDaniel Staub
Daniel Staub
BCBlai Coll
Blai Coll
FCFolkert J. Ten Cate
Folkert J. Ten Cate
ASArend F.L. Schinkel
Arend F.L. Schinkel

1 April 2012 in Ultrasound in Medicine & Biology
Verified
Journal Article
Closed access
GKGerrit Luit ten Kate
Gerrit Luit ten Kate
GRGuillaume Renaud
Guillaume Renaud
ZEYNETTIN AKKUSZEYNETTIN AKKUS
ZEYNETTIN AKKUS
SOStijn C.H. van Den Oord
Stijn C.H. van Den Oord
FCFolkert J. Ten Cate
Folkert J. Ten Cate
ASAntonius F.W. van der Steen
Antonius F.W. van der Steen